Dubai launch brief: dietary supplements and medical foods
Scope. This is a Dubai-focused commercial and regulatory briefing, using Dubai Municipality’s 2024 health-supplement guideline, UAE food-safety law, and recent third-party UAE market reports.[1][2] It is not legal advice; classification should be confirmed with the relevant authority before committing to artwork, inventory, or claims.
The decisive first step: classify the product before designing the launch
Dubai Municipality defines a health supplement as an ingested product containing a dietary ingredient intended to add nutritional value to the diet. It can include vitamins, minerals, botanicals, amino acids, enzymes, and pre-/probiotics, in forms such as tablets, capsules, softgels, liquids, or powders. A health supplement must be labelled as such and must not be intended to diagnose, treat, prevent, or cure disease.[1]
Medical food / food for medical purposes is not simply a “clinical supplement.” Dubai Municipality explicitly places foods for medical purposes outside the health-supplement category: they are processed or formulated for dietary management of patients, used under medical supervision, and intended for patients with impaired ability to take, digest, absorb, metabolize, or excern ordinary foods or nutrients. Its examples include nutrition for food allergy, cancer-treatment weight loss, stroke, and neurological disorders.[1] That distinction should drive product architecture, intended-use wording, channel, evidence package, and the regulatory pathway. A product with disease-facing language cannot be “solved” by registering it as a standard health supplement.
Practical classification screen
Likely health supplement: daily micronutrient, omega-3, probiotic for general adult use, collagen, sports nutrition powder, or botanical, with a nutritional/general-wellness or structure/function claim and no disease claim.[1]
Likely food for special medical purposes (FSMP): a formulation for dietary management of a defined patient population, under clinician supervision, especially where impaired intake, digestion, absorption, metabolism, or excretion is central to the product proposition.[1] FSMP is not interchangeable with the broader “food for special dietary use” universe, which also includes other category types such as infant or weight-control products. The current Gulf FSMP technical regulation, GSO 1366:2021, applies to people older than 12 months and distinguishes complete standard-nutrient foods, nutritionally incomplete or disease-adapted foods, metabolic-disorder formulas, and oral rehydration solutions.[3]
Infant/young-child formula or infant FSMP: keep separate from the >12-month FSMP screen. GSO 2106:2025 is a current Gulf technical regulation covering infant formula, follow-on formula, products for young children, and formulas for special medical purposes; confirm UAE adoption and the applicable version/clauses with the competent authority.[4]
High-risk “reclassify before launch” signals: artwork or digital copy mentioning treatment, prevention, cure, disease symptoms, post-bariatric use, diarrhoea/vomiting, sleep, sexual enhancement, or paediatric probiotics below age two. Dubai Municipality lists several of these outside the health-supplement category and prohibits medical claims for supplements.[1]
Dubai versus federal UAE: the regulatory differences that matter in practice
Dubai is not a separate country-level regulatory regime; a launch in Dubai sits under federal UAE requirements and also under Dubai-local controls. The operating error is to treat the choice as “Dubai Municipality or UAE federal authority.” For a supplement, the current public record points to layered obligations whose interaction must be confirmed for the exact SKU.[5][1]
| Topic | Federal UAE layer | Dubai-local layer | Practical implication |
|---|---|---|---|
| Institution and legal scope | The 2025 federal decree-law places food supplements within EDE’s scope and defines them as oral diet-support products without disease diagnosis/treatment/prevention.[5] | Dubai Municipality’s 2024 guideline defines and classifies health supplements for the Dubai market.[1] | Classification language must fit both layers; global “nutraceutical” terminology does not determine the route. |
| Product authorization | EDE marketing approval is required for medical products unless an exemption applies; the law says the EDE may set category-specific controls.[5] | The Dubai guideline says health supplements cannot be manufactured, imported, exported, advertised, sold, or distributed in Dubai unless registered in Montaji.[1] | Do not assume that an EDE approval makes Montaji irrelevant, or vice versa. Seek a written route decision on whether one, both, or an exemption/delegation applies. |
| Applicant and establishment | EDE marketing-approval applicants must be licensed as a marketing office, manufacturer, contract manufacturer, or designated medical warehouse; its separate supplement trading/manufacturing license covers manufacturing and import/export activities.[5][6] | Montaji’s guideline requires a Dubai-incorporated applicant or Dubai warehouse and a relevant Dubai trade activity; foreign manufacturers rely on a local agent.[1] | Corporate set-up and local agent/distributor arrangements need to satisfy both the federal establishment model and the local import/warehouse/trade-activity requirements where applicable. |
| Dossier focus | EDE’s public materials call for product summary, detailed active/inactive formula, pack/leaflet, agency authorization, animal-origin/alcohol/TSE documentation where relevant, halal certificate, declarations, and free-sale/pharmaceutical-product documentation.[7] | Dubai’s dossier emphasizes Free Sale Certificate, full formula and botanical part, analysis report, GMP, certified-lab testing, and may request halal, clinical substantiation, or safety assessment.[1] | Build one master dossier but maintain a route-specific document map; the overlap is substantial, but not complete. |
| Label and consumer information | EDE requires package/leaflet information consistent with marketing approval and states that at least Arabic and English must be used in internal leaflets, unless an exception is made.[5] | Dubai specifies on-pack components such as product identity, manufacturer/agent, origin, ingredients, dose/instructions, warnings, barcode, and batch/lot; the federal food rules also require clear Arabic food-label information.[1][2] | Artwork must be cleared against both approved product information and the local label checklist before printing. |
| Claims and advertising | EDE approval is required for medical-product promotion, including social media; the material must be truthful, evidence-supported, aligned to approved use, and disclose risks/side effects.[5] | Dubai requires Montaji pre-approval for advertising/promotional activity and prohibits disease-treatment/prevention claims for supplements.[1] | Use one claims library but verify which authority or authorities must clear each asset; marketplace and influencer content belong in the same process. |
| Import and local-market release | The federal law controls marketing approval and product/establishment conditions; the exact execution process can be further set by EDE rules.[5] | Dubai’s consumer-product process requires Montaji declaration/import clearance, importer code, registered product, label integrity, storage/transport compliance, and at least 50% remaining shelf life and six months minimum at entry.[8] | Do not ship solely against a product certificate: confirm the importer code, clearance process, and batch shelf-life before freight release. |
| Food and FSMP / medical-food concepts | The UAE food framework requires registration before circulation and prior written approval for foods for special uses or food with health claims; GSO 1366 distinguishes FSMP categories for people older than 12 months.[2][3] | Dubai’s supplement guideline excludes foods for medical purposes from the health-supplement category.[1] | Medical-food/FSMP concepts require a separate written category-pathway decision, not a supplement registration with stronger language. |
What this comparison does not establish: the retrieved public sources do not say precisely when EDE authorisation and Montaji registration are cumulative versus delegated or exempt for a particular product. The federal law permits further exemptions and delegation, so treat that answer as a pre-launch written-authority question—not as a legal inference.[5]
Regulatory route: federal EDE layer and Dubai controls must be reconciled
The original Dubai-only route was incomplete. Federal Decree-Law No. 38 of 2024 entered into force on 2 January 2025, places food supplements within the scope of the Emirates Drug Establishment (EDE), and defines them as oral products that support the diet without treating, diagnosing, or preventing disease.[5] The law provides that a medical product may not be imported, distributed, sold, displayed, re-marketed, used, or manufactured for circulation in the UAE without EDE marketing approval unless a defined exemption applies.[5]
EDE’s current public service for marketing authorization expressly includes food supplements. It lists a 45-working-day service time, a AED 5,000 general-sale pharmaceutical-product registration charge plus AED 100 application fee, five-year validity, and a prerequisite that the marketing-rights holder and manufacturer be registered with EDE before product registration.[7] EDE’s published documentation includes a detailed formula; pack/leaflet; animal-origin and TSE information where relevant; local-agency/authorization evidence; halal certificate; declarations addressing hormones, heavy metals, antibiotics, steroids, pork derivatives, and harmful substances; company/manufacturing-site details; and a free-sale/pharmaceutical-product certificate.[7]
Dubai Municipality’s 2024 guideline still states that a health supplement may not be manufactured, imported, exported, advertised, sold, or distributed in Dubai unless registered in Montaji; it describes a Dubai-incorporated applicant or Dubai warehouse with a relevant trade activity, and places foreign-brand registration responsibility on the local agent.[1] Its dossier includes Free Sale Certificate, full ingredient/botanical disclosure, analyses, GMP, certified-lab testing, and potentially halal, clinical-substantiation, or safety documents; it states five-year validity.[1]
Authority matrix and the launch-critical uncertainty
EDE — federal product authorization: Treat EDE marketing authorization as the baseline pathway for a standard dietary supplement after the 2025 federal law. The applicant must be an EDE-licensed marketing office, manufacturer, contract manufacturer, or marketing-rights-holder-designated medical warehouse, with QA/traceability, post-marketing follow-up, quality/batch evidence, GMP, and compliant package information.[5]
EDE — establishment/trading/manufacturing activity: EDE also publishes a separate nutritional-supplement trading/manufacturing licensing service, with a stated three-working-day service time and one-year validity for manufacturing and import/export activities; its page says retail/wholesale supplement trading/manufacturing establishments require EDE licensing.[6]
Dubai Municipality / Montaji: Montaji remains an explicit Dubai product-registration and advertising-control layer in the 2024 guideline, including local applicant/warehouse requirements, product dossier controls, inspections, and promotional approval.[1]
Federal/local coordination: The public sources reviewed do not establish whether every supplement presentation requires both an EDE authorization and a separate Montaji registration, whether a delegation/exemption applies, or which system is controlling for a particular presentation. The federal law allows further exemptions and delegation of powers.[5] Obtain written route confirmation from both EDE and Dubai Municipality for the exact product, applicant entity, import model, and sales channels before paying for inventory or committing to dates.
At the UAE food-law level, manufacturers, producers, and importers must register food before circulation; competent authorities may audit applications, request risk-based laboratory testing, and inspect imported/circulating food for registration and compliance.[2] This remains especially relevant for FSMP/food-for-special-use concepts, whose pathway should follow a written classification decision rather than the supplement route by analogy.
Import release, shelf life, and logistics: controls that sit between approval and sale
For the Dubai local market, the consumer-products import guideline requires consignment processing through Montaji’s Import/Re-export service and a valid importer code in the company profile. Products must already be registered to the applicable standard before import; the importer submits the clearance request and consignment details after arrival.[8] Registration alone therefore does not equal local-market release.
The same guideline states that imported consumer products should have at least 50% of their shelf life remaining and not less than six months at entry—not 12 months. Labels must be clear, indelible, and not easily removable, while transport and storage conditions must be observed.[8] Use this as a shipment-release gate in the supply agreement and demand a batch-level remaining-shelf-life calculation before booking freight.
For products on the food route, Dubai’s Food Code assigns the establishment responsibility for establishing shelf life under reasonably foreseeable distribution, storage, and use conditions. For high-risk/perishable prepacked foods, it calls for shelf-life validation and Food Control Department approval before label approval; it specifies that the study should consider factors including packaging, pH/water activity where relevant, environmental conditions, microbiological results, and storage/transport temperature.[9] The supplied checklist’s assertion of a universal Zone IVb stability-study requirement was not verified in the primary sources reviewed, so it is not presented here as a blanket Dubai rule.[10]
Channel architecture and marketplace controls
For consumer supplements, pharmacy-led omnichannel distribution is a practical entry route rather than a guarantee of listing. Life Pharmacy describes a UAE network of more than 600 retail outlets and an online offer spanning vitamins, sports nutrition, and baby care; myAster describes an online pharmacy with health/wellness assortments, pharmacy-network fulfillment, and same-day delivery in major UAE cities.[11][12] These are credible target-account types for a registered consumer product, alongside selected hypermarkets and specialist stores.
Large marketplaces can accelerate discovery and price comparison, but they should be treated as execution risk controls, not proof that a product is legal. Noon’s UAE supplement category contains listings for product types and claims that conflict with Dubai Municipality’s public banned-ingredient and prohibited-claim annexes—for example, melatonin, ashwagandha, shilajit, and weight-loss/sexual or disease-adjacent positioning.[13][14] A brand should therefore run a marketplace governance plan: authorize only the registered SKU and approved pack; reconcile seller identities; monitor titles, search terms, images, reviews reposted by the brand, and influencer content; and remove unapproved claims rather than relying on what competitor listings display.
For FSMP and other medically supervised nutrition, start with hospital dietetics, relevant specialists, and clinical procurement rather than retail media. This is a commercial design inference from the FSMP definition and should follow a written classification and authority-pathway decision; it is not evidence that any named hospital will list the product.[3][1]
Claims, label and advertising: the main launch failure points
Supplement labels must declare the product identity, manufacturer/agent details, country of origin, ingredients, pack size, production/expiry, storage, daily dose/instructions, intended use, warnings, barcode, and batch/lot. The guideline calls for clear English and/or Arabic declarations; federal food rules further require clear, true Arabic label information and origin/packing-country disclosure.[1][2] The health-supplement guideline requires a clear, unique barcode, but the retrieved primary materials do not establish that this must be a GS1 GTIN registered in a particular system. Nor do they prescribe the supplied checklist’s exact US-style disclaimer wording; they instead prohibit disease-treatment/prevention claims and require supplement facts, percentage daily values for vitamins/minerals, intended use, and warnings.[1][10]
The compliant claim space is general health, nutrient support, and substantiated structure/function language. Claims must be truthful, non-misleading, and supported by sound scientific evidence; vitamin/mineral supplementation claims are permitted only where the relevant nutrient exceeds 30% of RDA. Disease-treatment or prevention claims are prohibited whether explicit or implied, including on labels, leaflets, advertisements, and other communications.[1]
This applies well beyond the pack. Dubai Municipality’s 2024 guideline says promotional activity requires pre-approval through Montaji, explicitly including brochures, campaigns, social media, TV/media, and indoor/outdoor advertising.[1] The 2025 federal law separately prohibits advertising, publicity, or promotion of medical products by any medium, including social media, without EDE approval; it requires that the material be truthful, non-misleading, evidence-supported, consistent with approved uses, and disclose risks/side effects.[5] Until the authorities confirm the operational division of responsibility, route every asset—pack, marketplace listing, influencer script, paid media, sales training, and HCP materials—through a single claims library and seek approval in the confirmed system(s).
The controls that routinely decide whether a supplement can be launched
Formula screen: do this before formula lock, not after registration submission
The guideline makes formula review a regulatory exercise, not merely an R&D or quality exercise. It applies maximum daily limits to vitamins, minerals, and other ingredients by life stage. For adult products, examples include vitamin D at 100 µg/day, folic acid at 1,000 µg/day, vitamin C at 2,000 mg/day, vitamin E at 1,000 mg/day, calcium at 2,500 mg/day, iodine at 1,100 µg/day, iron at 45 mg/day, selenium at 400 µg/day, and zinc at 35 mg/day for men / 50 mg/day for women; magnesium above 350 mg/day requires a specific use/purpose statement.[14] These are daily exposure limits, so product architecture needs to account for the labelled daily serving, not just the per-capsule dose.
The guideline also lists ingredient-specific upper levels such as beta-carotene 18,000 µg/day, L-methionine 1,000 mg/day, lutein 20 mg/day, lycopene 30 mg/day, potassium 200 mg/day, inositol 650 mg/day, sodium 2,300 mg/day, and fluoride 10 mg/day for adults.[14] Treat the annexes as a formulation gate: verify the current annex against the authority immediately before submission because the guideline says its prohibited-ingredient list may be revised frequently.[1]
Botanical-combination rule: no published numerical plant cap was found
The public Dubai Municipality guideline permits a health supplement to contain “one or more or combinations” of dietary ingredients, including botanicals and herbs, with an exact dose.[14] Across the official materials reviewed, no maximum number of plant species per single health-supplement product was specified. Therefore, the control is not a plant-count limit; it is formulation-by-formulation evidence, identity, dose, safety, and claims control.
For every botanical in a multi-plant formula, the ingredient report should identify the scientific name, plant part, exact amount, and the manufacturer’s signed/stamped origin documentation. A safety assessment may be requested for an individual ingredient in a combination and/or for the entire product; this makes complex formulas progressively harder to substantiate and defend even without a numerical plant cap.[14] The practical rule is to keep the formula as simple as the intended benefit allows, reject each botanical on the current prohibited list before finalizing the blend, and avoid combining botanicals whose individual safety, identity, or claim rationale cannot be separately documented.[14]
Halal, animal-derived raw materials, and gelatin: dossier-level controls
Yes—halal and animal-origin requirements are now included, and this section makes them operational. Dubai Municipality may request a halal certificate that identifies the source of the animal ingredient and is issued by a recognized Islamic society in the country of origin.[14] The same guideline requires that animal-derived inputs do not introduce transmissible-spongiform-encephalopathy risk; its chemical-test annex states pork traces/gelatin must be absent.[14]
Under EDE’s public marketing-authorization materials, products with animal-derived substances require disclosure of the animal species, the part used, any alcohol percentage and reason for its use, documentary TSE/BSE information where applicable, a halal certificate from approved bodies, and a company declaration addressing pork derivatives along with hormones, heavy metals, antibiotics, steroids, and harmful natural/chemical substances.[7] Build an animal-origin packet for each raw material and excipient—not only the active ingredient—including capsule shell/gelatin, collagen, omega-3 source, lactose, enzymes, glycerin, flavour carriers, processing aids, and alcohol-containing extracts. This last list is an operating checklist inferred from the official animal-origin disclosure rule; its individual applicability must be confirmed against the actual bill of materials.[7]
Banned-ingredient screen: common global wellness ingredients are not automatically viable in Dubai
Dubai Municipality’s May 2024 annex lists numerous ingredients as banned or not applicable to health supplements. Commercially consequential examples include CBD/cannabidiol, cannabis, 5-HTP, DMAA, ephedra, bitter orange, DHEA, GABA, melatonin, St John’s wort, tongkat ali, lion’s mane, yohimbe, kava, silver/nanosilver, ashwagandha, and valerian.[14] L-tryptophan is listed as generally banned but may be used only as part of an amino-acid profile with a specified antidepressant/medication warning.[14] This is a high-value diligence item for sports, sleep, stress, sexual-wellness, metabolic, nootropic, botanical, and “adaptogen” portfolios: a formula legally sold in the US, UK, or EU may fail Dubai’s health-supplement route.
Quality-release design: the dossier needs testable specifications
The annex specifies microbiological and chemical expectations that should be written into supplier quality agreements and finished-product release specifications. E. coli, S. aureus, and Salmonella must be absent; yeast/mould must not exceed 300 CFU/g for amino-acid/vitamin/mineral products or 1,000 CFU/g for herbal products; coliforms must not exceed 10 CFU/g; and aerobic bacteria must not exceed 10,000 CFU/g for amino-acid/vitamin/mineral products or 100,000 CFU/g for herbal products.[14]
Quantitative vitamin/mineral assay must fall within 80–120% of label claim. The same annex gives adult daily limits for arsenic (10 µg), mercury (20 µg), lead (20 µg), and cadmium (6 µg); caps caffeine at 200 mg per single dose and 400 mg/day for healthy adults who are not pregnant or nursing; permits only 0.03% alcohol from simple fermentation (not added alcohol); and requires absence of pork traces/gelatin, sildenafil, sibutramine/phenolphthalein, and anabolic hormones.[14] For high-risk categories—botanicals, pre-workouts, weight-management, sexual-wellness, and sleep products—these analytes should be part of a pre-shipment certificate-of-analysis plan, not a response to a later authority sample.
Claims: a much narrower field than most global supplement brandbooks assume
The prohibited-claim annex is broader than the generic “no disease claims” rule. It explicitly covers cardiovascular conditions and cholesterol reduction, diabetes and thyroid disorders, gastrointestinal conditions including diarrhoea/constipation, immune disorders/allergies, obesity, osteoporosis and inflammatory/rheumatic claims, cancers, neurological conditions, asthma, skin diseases, conception/pregnancy/sexual dysfunction, and many other disease areas.[14] It separately prohibits language such as “miraculously,” “world’s best,” “100% safe,” “guaranteed,” “efficacious/effective,” “anti-aging,” “longevity,” unqualified “anti-stress,” IQ or memory enhancement, hormone regulation/enhancement, and sexual-power/arousal/libido claims.[14]
A workable claims hierarchy is therefore: (1) ingredient identity and nutrition facts, (2) general health/nutrient-support statements, and (3) narrow structure/function statements where the relevant evidence is documented. Any health claim needs sound and sufficient substantiation; structure/function claims require ingredient-level evidence and, where necessary, product-level evidence.[1] Do not assume that a claim allowed in a pharmacy training deck can be used in social ads, influencer content, a marketplace title, or consumer reviews that the brand reposts: the promotional-approval requirement explicitly covers social media and campaigns.[1]
What the market appears to reward
Third-party market forecasts agree on growth but not on market size: one estimates the UAE supplement market at US618 million in 2025 and 11.2% annual growth through 2033. Treat these as directional commercial indicators, not audited market facts.[15][16]
Several demand signals recur across those sources:
Core volume remains conventional: vitamins were estimated as the largest ingredient segment (27.2% in 2025); tablets led one source’s form split.[16]
Faster-growth formats may improve trial and adherence: gummies are projected to grow quickly, while convenient powders, ready-to-drink shakes, and single-serve formats are associated with fitness and busy urban lifestyles.[16]
Priority consumer propositions: immunity, general wellness, vitamin D/micronutrients, protein/amino acids, weight management, gut health, and beauty-from-within are repeatedly identified in the available market reporting.[16]
Channel is hybrid rather than digital-only: offline was estimated at 76.1% of 2025 sales in one report, supported by pharmacy/hypermarket reach and advice, while online sales are forecast to grow quickly through convenience, delivery, reviews, and subscriptions.[16]
For a medical-food proposition, the commercial opportunity should not be judged through wellness-market growth alone. The stronger starting point is a narrow, clinically defined use-case with a physician, dietitian, or hospital pathway; the guideline’s definition itself centers medical supervision and patient nutritional impairment.[1]
Medical foods: decision gates before a commercial commitment
The sources reviewed establish the legal boundary more clearly than they establish a single public, Dubai-specific product-registration checklist for every medical-food formulation. The federal food framework requires prior food registration, risk-based testing where required, and prior written approval for food for special uses or food with health claims; the health-supplement guideline separately excludes foods for medical purposes.[2][1] This is not a gap to bridge with assumptions. Obtain a written category/pathway confirmation before finalizing artwork, clinical claims, a hospital tender, or a first import.
For that request, prepare a concise classification package containing: the exact intended patient group; whether use is exclusive, partial, or supplemental feeding; the nutritional impairment addressed; the medical-supervision instruction; formula and full nutrition profile; proposed label and all HCP/consumer copy; serving regimen; stability/shelf-life and microbiological specifications; country-of-origin status; and evidence linking the formula to the dietary-management purpose. The elements are a practical submission package inferred from the official medical-food definition and the federal registration/inspection requirements, not a substitute for an authority-prescribed dossier.[1][2]
The commercial implication is material: a product whose differentiation rests on cancer cachexia, dysphagia, malabsorption, inborn metabolic disease, renal nutrition, or post-stroke feeding should be designed for clinical access, dietetic protocols, procurement, and supervised use. A consumer wellness launch with disease-oriented content creates a predictable classification and claims problem.[1]
Recommended launch plays
Consumer supplement: start with a low-regulatory-friction wedge
Choose one clearly supplement-classifiable product, an ingredient level inside the applicable limits, a defensible benefit statement, and a format matched to its occasion of use. The strongest early candidates from the market signals are: daily vitamin D/micronutrient support, protein/amino-acid recovery, gut-health formulations, and beauty-from-within offerings. Do not make disease-management the commercial hook; test general wellness and structure/function language against the dossier evidence before creative production.[1][16]
Medical food: begin with regulatory and clinical design, not brand marketing
Commission a pre-classification discussion and build a medical dossier around the patient population, nutritional requirement, supervisory use, formula rationale, safety, stability, and clinical-use evidence. Make hospital dietetics, specialist clinics, and medical distribution the initial route-to-market hypothesis. This is a strategic inference from the official definition—not confirmation of a separate approval route—and should be validated with the competent authority before launch.[1][2]
Build compliance into operating design
Establish the Dubai legal/importer/warehouse set-up and relevant trade activity before committing to a launch date.[1]
Create a dossier master file covering Free Sale Certificate, full formula and botanical identity, GMP, analyses, lab reports, and substantiation.[1]
Freeze Arabic/English label and claims after regulatory review; run every digital asset through the same clearance process.[1]
Design batch traceability, import release, adverse-event/complaint handling, and recall readiness before first shipment; authorities inspect registration and physical conformity and can initiate recalls.[1]
The principal risks to manage
Misclassification and claims creep are the largest risks. A supplement dossier does not make a disease-facing, medically supervised product compliant; conversely, a medical-food concept will require a route and commercial model that fit its clinical purpose.[1]
Formula evidence can fail late. Dubai’s guideline sets contamination, heavy-metal, restricted-ingredient, prohibited-ingredient, stability, packaging, GMP, and testing expectations, and notes that the banned-ingredient list may be revised frequently. Screen the full formula—including excipients, botanical part/source, and animal-derived materials—before selecting claims or ordering stock.[1]
Third-party market data is useful but should not determine the business case by itself. The conflicting 2025 market estimates above demonstrate why a launch plan should validate price architecture, sell-through, pharmacy listing terms, e-commerce conversion, and repeat purchase through local primary research and a controlled pilot.[15][16]
What remains outside the public-source record—and must be closed before launch
The brief is now broad on published requirements, but it does not claim that every rule is captured. The following items require product-specific written confirmation or access to the full applicable standard.[5]
Federal–Dubai allocation: whether the exact SKU needs EDE marketing authorization, Montaji registration, both, or a documented exemption/delegation.[5]
FSMP standard clauses: the publicly viewable GSO pages establish scope and categories, but not the full formulation, labeling, compositional, or evidence clauses for the particular medical-food class.[3][4]
Botanical identity and raw-material provenance: no numerical plant cap was found; each actual botanical/part/extract ratio, contaminant specification, and safety rationale needs approval against the current annexes and dossier review.[14]
Halal evidence chain: certificate issuer acceptance, scope of certificate, lot-to-lot raw-material traceability, processing aids, and any alcohol-derived ingredient need confirmation for the actual formula.[14][7]
Commercial access: retailer listing fees, distributor margin, marketplace seller controls, hospital formulary/tender processes, HCP-access rules, and any reimbursement are commercial negotiations or institution-specific requirements—not fixed by the regulatory sources reviewed.
The right final gate is a written authority query built around the complete bill of materials, label/leaflet, claims matrix, applicant entity, import flow, and intended channels. It should request a recorded classification and a list of approvals, standards, and documents required for that specific SKU.[5]
Approval-dependent launch plan: 90 days to readiness, not necessarily to sale
A 90-day calendar is credible for readiness work but not as a guaranteed commercial-launch date: EDE’s public marketing-authorization service alone states 45 working days, and the federal/Dubai interaction must be confirmed for the product.[7][5]
Weeks 1–2 — classify and route: lock intended use, target population, formula, and every claim; secure written EDE/Dubai Municipality pathway confirmation for the product, applicant, import model, and channel.
Weeks 2–5 — de-risk the formula and dossier: test ingredients and doses against applicable limits/restrictions; assemble Free Sale Certificate, analyses, GMP, stability/quality evidence, and product/pack information required by the confirmed pathway.[7][1]
Weeks 4–7 — establish applicant readiness and submit: secure the eligible EDE establishment/marketing-rights-holder arrangement and Dubai local operating set-up where required; prepare bilingual labels and submit the confirmed authorization/registration route(s).[5][1]
Weeks 6–10 — prepare channels conditionally: select pharmacy/hypermarket, D2C/marketplace, or clinical distribution; build listings and promotional materials but do not publish assets before confirmed advertisement approval.[5][1]
After all required approvals and import release — controlled commercial launch: seed a limited number of accounts/SKUs, then monitor sell-through, complaints, repeat purchase, and claims compliance. The operating design should preserve product registration, physical conformity, sampling, and recall readiness.[1]
The key decision is not “supplement versus medical food” as a marketing choice. It is whether the product’s intended use, patient population, evidence, and communications genuinely fit one regulatory category; that decision determines the relevant pathway and launch design.[1]
